Sun Pharma and Philogen Enter Exclusive Agreement for Anti-Cancer Immunotherapy

Tuesday, 1 October 2024, 00:19

Sun Pharma and Philogen have entered an exclusive agreement for the commercialization of an innovative anti-cancer immunotherapy, Fibromun. This partnership aims to treat soft tissue sarcoma and glioblastoma, addressing significant unmet medical needs. Sun Pharma will have worldwide rights to commercialize Fibromun following pivotal trials.
Financialexpress
Sun Pharma and Philogen Enter Exclusive Agreement for Anti-Cancer Immunotherapy

Collaboration Details

Sun Pharmaceutical Industries Limited and Philogen S.p.A announced their exclusive global licensing agreement for the anti-cancer immunotherapy Fibromun (L19TNF). According to the companies, Fibromun is currently under investigation through registration trials to treat soft tissue sarcomas and glioblastoma.

Agreement Highlights

  • Exclusive Worldwide Rights: Sun Pharma will exclusively commercialize Fibromun.
  • Clinical Trials: Philogen is responsible for completing ongoing pivotal clinical trials and pursuing marketing authorization.
  • Manufacturing: Philogen will also handle the manufacturing of commercial supplies.
  • Financial Arrangement: Post-commercialization economics will be shared in a 45:55 ratio.

"Fibromun's progress through development has been quite encouraging and has the potential to be an important treatment option for soft-tissue sarcomas and other cancers with significant unmet medical needs," said Dilip Shanghvi, Chairman of Sun Pharma. This partnership expands Sun Pharma’s oncology pipeline, complemented by their existing work in skin cancers.

Future Prospects

Philogen’s CEO, Prof. Dr. Dario Neri, emphasized the goal of making Fibromun widely available to patients. Previous research shows Fibromun's promising therapeutic activity in glioblastoma, inducing long-lasting anti-tumor responses in some patients. An independent board has recommended the continuation of trials, reflecting the strong commitment both companies share toward Fibromun's development.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe